Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting

Acta Neurobiologiae Experimentalis

Volumn 72, Issue 3, 2012, Pages 264-271

  Malnar, Martina ^a   Kosicek, Marko ^a   Bene, Raphael ^b   Tarnik, Iva Petek ^b   Pavelin, Sanda ^c   Babic, Ivana ^d   Brajenovic Milic, Bojana ^d   Hecimovic, Hrvoje ^b   Titlic, Marina ^c   Trkanjec, Zlatko ^b   Demarin, Vida ^b   Hecimovic, Silva ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c UNIVERSITY HOSPITAL SPLIT   (Croatia)

^d UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

Alzheimer's disease; Amyloid ; Biomarkers; Cerebrospinal fluid; Diagnosis; Tau

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NONPARAMETRIC TEST; PSYCHOLOGICAL RATING SCALE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PSYCHIATRIC STATUS RATING SCALES; STATISTICS, NONPARAMETRIC; TAU PROTEINS;

EID: 84869061177     PISSN: 00651400     EISSN: 16890035     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.
2. Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6: 734-746.
3. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM 2007. Cerebrospinal fluid tau/betaamyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64: 343-349.
4. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117.
5. Folstein MF, Folstein SE, McHugh PR 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
6. Gauthier S, Dubois B, Feldman H, Scheltens P (2008) Revised research diagnostic criteria for Alzheimer's disease. Lancet Neurol 7: 668-670.
7. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L 2006. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5: 228-234.
8. Hixson JE, Vernier DT 1990. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31: 545-548.
9. Hort J, Bartos A, Pirttila T, Scheltens P 2010. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur J Neurol 17: 90-96.
10. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H 1999. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52: 1555-1562.
11. Mattsson N, Blennow K, Zetterberg H 2010. Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clin Chem Lab Med 48: 603-607.
12. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de LM, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K 2009. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302: 385-393.
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
14. Miller JM, Pliskin NH 2006. The clinical utility of the Mattis Dementia Rating Scale in assessing cognitive decline in Alzheimer's disease. Int J Neurosci 116: 613-627.
15. Miller SA, Dykes DD, Polesky HF 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
16. Morris JC 2005. Mild cognitive impairment and preclinical Alzheimer's disease. Geriatrics Suppl: 9-14.
17. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A 2002. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59: 1729-1734.
18. Riemenschneider M, Schmolke M, Lautenschlager N, Guder WG, Vanderstichele H, Vanmechelen E, Kurz A (2000) Cerebrospinal beta-amyloid (1-42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. Neurosci Lett 284: 85-88.
19. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ (1993) Association of apolipoprotein E allele epsilon 4 with lateonset familial and sporadic Alzheimer's disease. Neurology 43: 1467-1472.
20. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH 2011. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280-292.
21. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T 2009. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66: 382-389.